Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study)

Lupus

Volumn 25, Issue 5, 2016, Pages 479-485

  Bazzan, M ^a   Vaccarino, A ^a   Stella, S ^a   Sciascia, S ^d   Montaruli, B ^b   Bertero, M T ^b   Carignola, R ^c   Roccatello, D ^d   Osvaldo, Giachino ^e   Binello, Giovanni ^e   Luisa, Sosso ^e   Valeria, Data ^e   Patrizia, Bigo ^e   Cristiana, Rollino ^e   Michela, Ferro ^e   Eirini, Karvela ^e   Raffaele, Pellerito ^e   Emanuela, Bellis ^e   Piercarla, Schinco ^e   Piera, Sivera ^e   Anna, Kuzenko ^e   Emanuela, Napolitano ^e   Domenico, Cosseddu ^e   Cristiana, Marchese ^e   Nicoletta, Romeo ^e   Giulia, Seminara ^e   Maria, Stefanidou Erato ^e   Molinari, Filippo ^e   Contino, Laura ^e   Gabriella, Nallino Maria ^e   Calvi, Roberta ^e   Stratta, Piero ^e   Bizzocchi, Agata ^e   Bobbio, Flavio ^e   Sainaghi, Pier Paolo ^e   Sola, Daniele ^e   more..

^a MOLINETTE HOSPITAL   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e NONE

Author keywords

Anticoagulation; antiphospholipid syndrome; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; THROMBOSIS; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES COMPLICATIONS; INCIDENCE; ITALY; MIDDLE AGED; ODDS RATIO; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL MODEL; THROMBOPHILIA; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BIOMARKERS; DIABETES COMPLICATIONS; FEMALE; HUMANS; INCIDENCE; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962542199     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315617538     Document Type: Article

References (26)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
3. Garcia D, Akl EA, Carr R, et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122: 817-824.
4. Bazzan M, Vaccarino A, Stella S, et al. Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun Rev 2013; 12: 826-831.
5. Pengo V, Ruffatti A, Legnani C, et al. Incidence of first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multi center prospective study. Blood 2011; 118: 4710-4718.
6. Tincani A, Andreoli L, Casu C, et al. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus 2010; 19: 432-435.
7. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-242.
8. Ruiz-Irastorza G, Kamashta MA, Hunt BJ, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Arc Int Med 2002; 162: 1164-1169.
9. Hernandez-Molina G, Espericueta-Arriola G, Cabral AR,. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rrheumatol 2013; 31: 382-388.
10. Lim W,. Thrombotic risk in the antiphospholipid syndrome. Sem Thromb Hemost 2014; 40: 741-746.
11. Forastiero R,. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 2014; 23: 1252-1254.
12. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
13. Giron-Gonzales JA, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560-1567.
14. Levine SR, Brey RL, Tilley SC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584.
15. Ames PR, Ciampa A, Margaglione M, et al. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation. Thromb Haemost 2005; 93: 694-699.
16. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
17. Okuma H, Kitagawa Y, Yasuda T, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2010; 7: 15-18.
18. Bertero MT, Bazzan M, Carignola R, et al. Antiphospholipid syndrome in northwest Italy (APS 'Piedmont Cohort'): demographic features, risk factors, clinical and laboratory profile. Lupus 2012; 21: 806-809.
19. Garcia DA, Kamasta MA, Crowter MA,. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 2007; 110: 3122-3127.
20. Giannakopoulos B, Krilis S,. How I treat the antiphospholipid syndrome. Blood 2009; 114: 2020-2030.
21. Pengo V, Denas G, Banzato A, et al. Secondary prevention in thrombotic antiphspholipid syndrome. Lupus 2012; 21: 734-735.
22. Keeling D, Mackie I, Moore GW, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47-58.
23. thInternational Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-218.
24. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.
25. Brandt JT, Barna LK, Triplett DA,. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-1603.
26. Les I, Ruiz-Irastorza G, Khamashta MA,. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Sem Thromb Hemost 2012; 38: 339-347.